Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen, Merck To Test New Immunotherapy Combination

This article was originally published in Scrip

Executive Summary

Amgen Inc. and Merck & Co. Inc. inked a collaboration agreement to test their antibody therapies Blincyto (blinatumomab) and Keytruda (pembrolizumab) in patients with diffuse large B-Cell lymphoma (DLBCL) in a Phase Ib/III clinical trial.

Advertisement

Related Content

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Topics

Advertisement
UsernamePublicRestriction

Register